Lundbeck Receives Marketing Authorization For Vyepti In Japan For The Prevention Of Migraine Attacks

H. Lundbeck received Japanese marketing authorization for Vyepti (eptinezumab), enabling the company to offer its preventive migraine therapy to adult patients in Japan. The approval expands Lundbeck's addressable market in migraine treatment and represents a commercially positive regulatory milestone, though no revenue guidance or sales estimate was disclosed.